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Introduction {#sec1}
============

Pluripotent stem cells (PSCs) harbor core properties of self-renewal and pluripotency ([@bib8], [@bib15]). Mouse embryonic stem cells (mESCs), established from the inner cell mass (ICM) of preimplantation blastocysts, are classically derived from a permissive 129-strain and kept in serum-containing medium supplemented with leukemia inhibitory factor (LIF). They are considered to possess "naive" pluripotency. Bone morphogenetic proteins (BMPs) have been shown to substitute for serum and sustain self-renewal of naive mESCs together with LIF ([@bib24]). On the other hand, human ESCs, which have characteristics similar to those of mouse epiblast stem cells (mEpiSCs) derived from postimplantation embryos, are more mature and are referred to as being "primed" for differentiation. These cells are LIF independent, and are usually maintained in the presence of fibroblast growth factor 2 (FGF2) and activin A, which stabilize the primed pluripotent state.

Although the serum-free medium supplemented with LIF and BMP-4 is well established, PSCs maintained with BMP-4 are rather exceptional. To derive mESCs from non-permissive strains, suppression of the differentiation-inducing mitogen-activated protein kinase kinase 1/2 (MEK1/2)-extracellular signal-regulated kinase 1/2 (ERK1/2) pathway is required (i.e. LIF+BMP-4+MEK1/2i) ([@bib2]). A cocktail of two inhibitors, i.e. for the MEK1/2 and GSK3 pathways (2i), has been proved to be sufficient to maintain mESCs with full pluripotency, or a "ground state" ([@bib25]), and LIF supplementation (2i+LIF, or 2iL) strengthens the robustness. In the ground state, the BMP-SMAD pathway has been shown to be less active ([@bib4]). Furthermore, BMP-4 induces differentiation of primed pluripotent cells. Thus, clarifying the role of BMP in mESCs from permissive strains will provide important clues for the molecular basis of naive pluripotency.

BMPs are members of the transforming growth factor β (TGF-β) family, and transduce their signals through distinct sets of type I and type II receptors ([@bib6], [@bib16]). Activated type I receptors phosphorylate receptor-regulated SMAD proteins (R-SMADs; SMAD1, SMAD5, and SMAD8 in the BMP signaling pathway, and SMAD2 and SMAD3 in the TGF-β/activin pathway), which form heterotrimeric complexes with SMAD4 and translocate into the nucleus. SMAD complexes are recruited to cell-type-specific binding sites through interaction with master transcription factors, controlling the expression of specific target genes ([@bib18]). In naive mESCs, SMAD1 has been reported to co-localize with OCT4, SOX2, and NANOG (abbreviated as OSN) and STAT3 on ESC-specific enhancers ([@bib5]). Consistently, the BMP-SMAD target genes *Id1* and *Dusp9* play critical roles in naive mESCs ([@bib13], [@bib24]). However, the existence of *Smad4* homozygous mutant mESCs ([@bib19]) suggests that the SMAD pathway is not required for maintenance of naive pluripotency, leading us to revisit the roles of the BMP-SMAD pathway in PSCs.

In the present study, we have performed both RNA-sequencing and SMAD1/5 genome-wide chromatin immunoprecipitation and sequencing (ChIP-seq) analyses of mESCs in the naive or primed states, and have employed a genome editing method. We show that the BMP-SMAD pathway is dispensable for maintaining naive pluripotency. Instead, BMP utilizes the MEK5-ERK5 pathway, which induces *Klf2*, an essential factor for the ground state ([@bib23]). Our study thus sheds important light on the molecular mechanisms underlying naive pluripotency.

Results {#sec2}
=======

BMP Target Genes Are Expressed at Comparable Levels in Both Naive and Primed mESCs {#sec2.1}
----------------------------------------------------------------------------------

Recent work has shown that naive mESCs can convert into LIF-independent EpiSC-like cells when cultured with FGF2 and activin A, which have been designated mESC-derived (mESD) EpiSCs or mEpiLCs ([@bib10], [@bib26]). We directly compared mESCs (E14, 129/Ola strain) in the naive and primed states ([Figure 1](#fig1){ref-type="fig"}A). Whole transcriptome analysis showed that expression of EpiSC lineage markers, e.g. *Fgf5*, *Dnmt3b*, and *Lefty1*, were upregulated, while genes associated with naive pluripotency, e.g. *Klf2*, *Klf4*, *Esrrb*, and *Zfp42* (also known as *Rex1*), were downregulated in mESD-EpiSCs ([Figures 1](#fig1){ref-type="fig"}B, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B). Our analysis also revealed that mESD-EpiSCs possessed a gene expression pattern similar to that of mEpiSCs and clustered separately from mESCs ([Figure S1](#mmc1){ref-type="supplementary-material"}C). In addition, trophoblastic markers, e.g. *Cdx2*, and mesodermal markers, e.g. *T(Brachyury)* and *Mesp1*, were induced in mESD-EpiSCs after BMP-4 treatment, which is not the case in naive mESCs in LIF+BMP-4 ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Importantly, expression levels of BMP target genes, *Id1* and *Dusp9*, were comparable or even higher in mESD-EpiSCs treated with BMP-4 (24 hr) than in mESCs ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B), suggesting that induction of these genes is not associated with the maintenance or reversion to the naive state.

SMAD1 and SMAD5 Bind to Enhancer Regions Together with KLF4 and KLF5 in Naive mESCs {#sec2.2}
-----------------------------------------------------------------------------------

To address the roles of the BMP-SMAD pathway, we performed ChIP-seq analyses ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}D). SMAD1/5 were enriched in the promoter regions of *Pou5f1* (which encodes OCT4) and *Nanog* in naive mESCs, as well as a positive control region in the *Id1* promoter. Consistent with previous findings ([@bib5]), the regions bound by SMAD1/5 were enriched with active enhancer marks (H3K4me1, H3K27ac, and co-activator p300) ([Figure 1](#fig1){ref-type="fig"}D). The SMAD1/5 binding regions were co-occupied by KLF4 and KLF5, but not by KLF2, as well as by the core regulators of pluripotency, OSN ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}E). To investigate whether SMAD1/5-KLF4/5 co-localized with OSN ([@bib5]), we subdivided the SMAD1/5 binding sites into three groups based on overlap with H3K4me1 (one of the enhancer marks) and OSN. KLF4/5 co-localized with SMAD1/5 even in OSN-negative enhancers (group 2, [Figure 1](#fig1){ref-type="fig"}F), and binding motifs for KLF4/5 were enriched in group 2 ([Figure 1](#fig1){ref-type="fig"}G). Moreover, distinct gene ontologies were enriched in group 2 compared with OSN-positive enhancers (group 1) ([Figure 1](#fig1){ref-type="fig"}H).

Motif enrichment analysis also showed that a binding motif for SMAD1/5, i.e. GC-rich SMAD Binding Element (GC-SBE) ([@bib17]), and that for SMAD4 and SMAD3, i.e. SMAD Binding Elements (SBE), were not enriched in SMAD1/5 binding sites of mESCs. Intriguingly, these motifs were enriched in those of mESD-EpiSCs ([Figure 1](#fig1){ref-type="fig"}G). Thus, it is possible that SMAD1/5 recognize enhancer regions indirectly through KLF4 and KLF5 in naive mESCs, while they recognize their target regions directly in primed mESCs ([Figure S1](#mmc1){ref-type="supplementary-material"}F).

KLF4 Physically Interacts with SMAD1 and Suppresses Its Activity {#sec2.3}
----------------------------------------------------------------

We next examined the relationship between SMADs and Krüppel-like factors (KLFs). Because of high overlap in binding between KLF4 and KLF5 ([Figure 2](#fig2){ref-type="fig"}A), we assumed that KLF4/5 recognized similar binding regions and that different efficiency of the ChIP procedures may explain the difference. We thus performed functional screening for KLFs using a BMP reporter, BRE-luc ([@bib17]). Ectopic expression of SMAD1 enhanced the activity of BRE-luc, while co-expression of KLF4 strongly attenuated the effect of SMAD1 ([Figure 2](#fig2){ref-type="fig"}B). Similarly, the BMP-4-induced BMP reporter activation was attenuated by KLF4 co-expression ([Figure 2](#fig2){ref-type="fig"}B).

Moreover, SMAD1 was co-immunoprecipitated with KLF4 in HEK293T cells ([Figure 2](#fig2){ref-type="fig"}C). The interaction with KLF4 was mapped to the MH2 domain of SMAD1 ([Figure 2](#fig2){ref-type="fig"}D). We also confirmed that endogenous KLF4 protein was co-immunoprecipitated with SMAD1/5 in naive mESCs ([Figure 2](#fig2){ref-type="fig"}E). Thus, KLF4 physically interacts with SMAD1/5 and suppresses transcriptional activity of SMADs, suggesting that the activity of BMP-SMAD is low in naive mESCs.

The BMP-SMAD Pathway Is Dispensable for Maintaining Naive Pluripotency {#sec2.4}
----------------------------------------------------------------------

To evaluate the BMP-SMAD pathway in naive mESCs, we generated artificial reporter constructs that minimized possible contributions of other transcription factors. Previously, we identified and characterized GC-SBE ([Figure S2](#mmc1){ref-type="supplementary-material"}A), a palindromic GGCGCC sequence (abbreviated as GC) that has strong affinity compared with GGAGCC (or GA), both of which exist in SMAD1/5 binding regions in the genome ([@bib17]). We thus generated BMP reporter constructs containing GC-SBE (GC/GA) as well as SBE ([Figure 3](#fig3){ref-type="fig"}A). The two BMP reporters had different sensitivity to BMP stimulation in cultured cells ([Figure S2](#mmc1){ref-type="supplementary-material"}B). They also responded faithfully to BMP signaling in transgenic zebrafish in vivo ([Figures 3](#fig3){ref-type="fig"}B, [S2](#mmc1){ref-type="supplementary-material"}C, and S2D). To perform negative selection, we chose the 3xGA construct with lower sensitivity, since BMPs are present in serum at concentrations of 2--6 ng/ml ([@bib11]).

We then generated lentiviruses harboring 3xGA-*GFP* or herpes simplex virus type 1 (HSV-1) thymidine kinase (TK) gene ([Figure 3](#fig3){ref-type="fig"}A), and introduced them into mESCs. As expected, GFP protein expression was regulated by BMP-4 ([Figure S2](#mmc1){ref-type="supplementary-material"}E). When the cells were maintained in LIF+BMP-4, a subpopulation of cells became strongly positive for GFP ([Figure 3](#fig3){ref-type="fig"}C). The subpopulation could be abolished by the addition of ganciclovir in 3xGA-*TK* cells and the remaining cells were alkaline phosphatase (AP) positive ([Figure 3](#fig3){ref-type="fig"}D). This suggested that strong activation of the BMP-SMAD pathway is not required for the maintenance of naive pluripotency.

To directly examine the roles of the BMP-SMAD pathway, we generated *Smad1* and *Smad5* double-knockout (*Smad1/5* dKO) and *Smad4* knockout (*Smad4* KO) mESCs using CRISPR-Cas9 genome editing ([Figure S2](#mmc1){ref-type="supplementary-material"}F) ([@bib14]). We established two different clones with biallelic mutations around the Cas9 target sites; mutants were screened by western blotting and confirmed by sequencing of the target regions ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H, data not shown). *Smad1/5* dKO lines and *Smad4* KO lines did not respond to BMP-4, or treatment with both BMP-4 and activin A, respectively ([Figures 3](#fig3){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}I). Similar to *Smad4* KO lines ([Figure S2](#mmc1){ref-type="supplementary-material"}J) ([@bib19]), *Smad1/5* dKO lines formed AP-positive colonies in LIF+serum and LIF+BMP-4 ([Figure 3](#fig3){ref-type="fig"}F), with growth rates comparable to those of parental mESCs ([Figure 3](#fig3){ref-type="fig"}G). *Smad1/5* dKO lines also showed comparable expression levels of pluripotency markers with parental mESCs ([Figure 3](#fig3){ref-type="fig"}H). We also examined TFE3 protein localization; TFE3 stays in the nucleus when cells are in the naive state, while it shifts to the cytoplasm when cells start to differentiate ([Figure S2](#mmc1){ref-type="supplementary-material"}K) ([@bib3]). TFE3 was localized mainly in the nucleus in *Smad1/5* dKO lines in LIF+serum ([Figure 3](#fig3){ref-type="fig"}I). Collectively, our observations suggest that the BMP-SMAD pathway is dispensable for maintaining naive pluripotency.

The MEK5-ERK5 Pathway Mediates BMP-4-Induced Self-Renewal of mESCs {#sec2.5}
------------------------------------------------------------------

What mechanisms can explain the role of BMP in maintaining naive pluripotency, if the BMP-SMAD pathway is dispensable? In addition to the SMAD proteins, BMP/TGF-β type I receptors activate non-SMAD signaling pathways, e.g. ERK and p38 mitogen-activated protein (MAP) kinase pathways ([@bib6], [@bib16]). Using mESCs in LIF+BMP-4, we screened a set of kinase inhibitors targeting non-SMAD pathways. In addition to the extracellular BMP antagonist NOGGIN, inhibitors for MEK5 (BIX 02189) and ERK5 (XMD 8--92) suppressed cell growth and promoted differentiation of mESC ([Figures 4](#fig4){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A); the effects of MEK5i on differentiation was weaker than ERK5i, which may be caused by off-target effects of MEK5i on MEK1/2. Consistently, BMP-4 treatment induced ERK5 phosphorylation in both mESCs and *Smad1/5* dKO mESCs ([Figures 4](#fig4){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B). Furthermore, we introduced either the constitutively active S311D/T315D mutant of MEK5 (MEK5DD), or the dominant-negative S311A/T315A mutant (MEK5AA) ([Figure 4](#fig4){ref-type="fig"}C) ([@bib20]). Among known target genes, e.g. *Id1* ([@bib20]) and *Klf2/4* ([@bib21]), MEK5DD induced *Klf2* in mESCs ([Figures 4](#fig4){ref-type="fig"}D and 4E). Intriguingly, MEK5AA suppressed and MEK5DD stimulated cell growth ([Figure 4](#fig4){ref-type="fig"}F). MEK5DD-expressing mESCs maintained ES-like morphology, while cells with the constitutively active S218D/S222D mutant of MEK1 (MEK1DD) underwent differentiation ([Figure 4](#fig4){ref-type="fig"}G).

To further confirm the roles of the MEK5-ERK5 pathway in self-renewal of naive mESCs, we used mESCs from the C57BL/6 mouse strains (BL6-mESCs), which cannot be kept in the feeder-free LIF+BMP-4 condition ([@bib2]). Again, MEK5DD induced both mRNA and protein of *Klf2* in BL6-mESCs ([Figures 4](#fig4){ref-type="fig"}D and 4E). In addition, similar to overexpression of KLF2 which can replace MEK1/2i ([@bib23]), MEK5DD-expressing mESCs maintained undifferentiated colony morphology in serum-free LIF+GSK3i ([Figures 4](#fig4){ref-type="fig"}H, 4I, [S3](#mmc1){ref-type="supplementary-material"}C, and S3D). The phenotype was mediated by the MEK5-ERK5 pathway, since it was disrupted by MEK5i and ERK5i ([Figures 4](#fig4){ref-type="fig"}I, [S3](#mmc1){ref-type="supplementary-material"}C, and S3D). Thus, our study revealed an important role of the MEK5-ERK5 pathway to maintain naive pluripotency ([Figure S3](#mmc1){ref-type="supplementary-material"}E).

Discussion {#sec3}
==========

BMP ligands induce the outgrowth of ICM during the derivation of mESC lines ([@bib7], [@bib24]). Inactivation of either *Bmp4* or *Bmpr1a* (which encodes ALK3) in mice results in early embryonic lethality due to impaired growth of the epiblast as early as embryonic day 6.5 (E6.5). However, *Smad1-* and/or *Smad5*-deficient mice exhibit abnormalities in extra-embryonic tissue development and angiogenesis from E7.5 or later ([@bib6]). In addition, *Bmpr1a* KO mESCs show self-renewal defects, while BMP-7 can rescue the defects through ALK2 activation ([@bib7]). Interestingly, activin/ALK4 can partially rescue the self-renewal defects of *Bmpr1a* KO mESCs ([@bib7]), suggesting that BMP and activin commonly activate non-SMAD pathway(s) and regulate the proliferative activity of epiblast at an early stage of development. Consistently, *Smad1/5* dKO mESCs and *Smad4* KO mESCs exhibit characteristics of naive pluripotency when maintained in LIF+serum ([Figures 3](#fig3){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}) ([@bib19]).

KLFs are zinc finger proteins that belong to the Specificity protein (Sp)/KLF family of transcription factors. Among them, Sp1 has been shown to cooperate with SMAD transcription factors ([@bib6]). KLF2/4/5 contain conserved zinc finger DNA binding domain in the C-terminal regions and are functionally redundant in naive mESCs ([@bib12]). However, recent reports described that KLF4/5 are targets of LIF-STAT3 and NANOG, while KLF2 protein is a direct target of ERK2 MAP kinase ([@bib1], [@bib9], [@bib23]), suggesting that KLF4/5 and KLF2 have distinct functions. In addition, we revealed that KLF4, but neither KLF2 nor KLF5, physically interacts with SMAD1 and suppresses the transcriptional activity of SMAD complex ([Figure 2](#fig2){ref-type="fig"}). Thus, KLF4 has additional properties by interacting with SMAD1 possibly through the N-terminal region, which is divergent among KLF2/4/5.

To conclude, we have dissected the roles of BMP signaling in self-renewal of naive mESCs and have illustrated that BMP exerts its self-renewing effect through distinct functions of different KLFs. BMP can both strengthen naive pluripotency through ERK5-KLF2 and induce differentiation via other pathways ([Figure S3](#mmc1){ref-type="supplementary-material"}E). The balance between the two pathways determines the effect of BMP signaling in mESCs; suppression of the SMAD pathway through LIF-STAT3-KLF4 and application of the MEK1/2 inhibitor can help to sustain the naive pluripotency. Our findings demonstrate an important role of the MEK5-ERK5 pathway in mESCs. Future studies will aim to elucidate the roles of ERK5, which can be activated by BMP, TGF-β/activin and FGF2, in PSCs of mouse and other species.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

Feeder-free E14 mESCs were maintained in media containing 15% fetal bovine serum or in the serum-free LIF+BMP-4 condition. Differentiation and maintenance of ESD-EpiSCs were essentially as described by [@bib26]. C57BL/6-background mESCs were maintained in the feeder-free 2iL condition. For details see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec4.2}
--------------------

All data are reported as the mean ± SEM. The difference between experimental groups were analyzed using Student\'s t test, with p \< 0.05 being considered significant.

Zebrafish Experiments {#sec4.3}
---------------------

All zebrafish experiments were carried out in compliance with the guidelines at the Zebrafish Technology Platform, Science for Life Laboratory, Uppsala University.
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![SMAD1 and SMAD5 Bind to Enhancer Regions Together with KLF4 and KLF5 in mESCs\
(A) Upper: Schematic of the mESC differentiation system used to derive EpiSC-like cells (ESD-EpiSCs). Lower: Morphology and alkaline phosphatase (AP) activity (inset) of mESC and ESD-EpiSC. Scale bar, 200 μm.\
(B) Transcriptome changes between mESCs and mESD-EpiSCs. Each point represents FPKM (fragments per kilobase of exon per million fragments mapped) values of a gene. Genes with FPKM \<0.1 in both conditions were excluded.\
(C) Representative view of SMAD1/5 binding sites within the *Id1*, *Pou5f1 (Oct4)*, and *Nanog* gene loci.\
(D) Heatmap representation of the locations of the indicated histone marks in mESCs within the 10-kb region surrounding the center of the SMAD1/5 peaks. For each of the 9,387 SMAD1/5-bound sites (y axis), the presence of epigenetic marker ([@bib22]) is displayed.\
(E) Transcription factors which co-occupy target sites with SMAD1/5 in mESCs in LIF+serum. Percentage of co-occupancy is presented.\
(F) SMAD1/5 binding sites in mESCs were subdivided into three groups based on co-localization with the enhancer mark H3K4me1 and core pluripotent transcription factors, i.e. OCT4, SOX2, and NANOG (OSN).\
(G) Enrichment of transcription factor binding sites (TFBSs) in the SMAD1/5 binding regions. Twenty sets of non-overlapping matched genomic control sequences were used as background control, presented as box plots.\
(H) For each subgroup, gene ontology (GO) analysis was performed. The top three GO biological processes are presented together with the p value.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![KLF4 Physically Interacts with SMAD1 and Suppresses Its Activity\
(A) Venn diagram indicating overlap of SMAD1/5 and KLF4/5 binding sites.\
(B) Functional interaction between SMAD1 and KLF4. Mouse ESCs were transfected with BRE-luc reporter construct together with KLFs as indicated, and the BMP-SMAD pathway was activated by ectopic SMAD1 expression or BMP-4 treatment. The medium was changed to N2B27 basal medium at 24 hr after transfection. At the same time, cells were treated with or without 50 ng/ml BMP-4 as indicated for 16 hr. Data represent means ± SEM of three independent experiments; ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.\
(C) Immunoprecipitation of FLAG-tagged KLFs or OCT4, followed by western blotting for HA-tagged SMAD1 in HEK293T cells.\
(D) Mapping of the SMAD1 domain responsible for KLF4 interaction. FLAG-tagged proteins were immunoprecipitated (IP), followed by western blotting for HA-tagged KLF4 in HEK293T cells. Full-length (FL), and MH1+L (linker) and MH2, containing amino acids 1--267 and 268--465 of SMAD1, respectively.\
(E) Immunoprecipitation (IP) of endogenous SMAD1/5 protein, followed by western blotting for KLF4 in E14 mESCs.](gr2){#fig2}

![BMP-SMAD Pathway Is Dispensable for Maintaining Naive Pluripotency\
(A) Schematic presentation of BMP reporter constructs. Fragments with GGCGCC (GC) or GGAGCC (GA) sequences together with SBE were triplicated and fused with reporter genes. TK, herpes simplex virus type 1 thymidine kinase gene.\
(B) A BMP type I receptor inhibitor, DMH1 (5 μM), attenuated GFP expression in Tg(3xGA-*GFP*) transgenic fish in vivo. Control, head to the right position; DMH1, head to the left position.\
(C) Expression of GFP in 3xGA-*GFP* cells in LIF+serum or LIF+BMP-4. Scale bar, 40 μm.\
(D) Negative selection with ganciclovir (GCV) in 3xGA-*TK* cells. Upper: Phase contrast. Lower: AP staining. Scale bar, 200 μm.\
(E) qRT-PCR analysis to evaluate BMP responsiveness. Cells were stimulated with 50 ng/ml BMP-4 or 50 ng/ml activin A for 1.5 hr. Data represent means ± SEM of three independent experiments. ^∗∗∗^p \< 0.001 versus parental mESCs. S15 dKO, Smad1/5 double knockout​.\
(F) Morphology (left) and AP activity (right) of *Smad1/5* dKO lines in LIF+serum and LIF+BMP-4. Scale bar, 200 μm.\
(G) Proliferation and doubling time (Td) of parental mESCs and *Smad1/5* dKO cell lines maintained in LIF+serum. A representative growth curve data is shown. Td (mean ± SEM) was calculated using three independent experiments.\
(H) qRT-PCR analysis of *Smad1/5* dKO cell lines cultured in LIF+serum. Data represent means ± SEM of three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01 versus parental mESCs.\
(I) Expression and localization of TFE3 (green), DNA/DRAQ5 (blue), and their merge in *Smad1/5* dKO lines in LIF+serum. Scale bar, 20 μm.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![The MEK5-ERK5 Pathway Mediates BMP-4-Induced Self-Renewal of mESCs\
(A) Screening for the effects of low molecular weight kinase inhibitors which target components of non-SMAD pathways using colony-forming assays. Cells were maintained in LIF+BMP-4 supplemented with indicated inhibitors for 4--5 days. Left: Data represent means ± SEM of three independent experiments; ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus DMSO. Right: Representative morphology of the colonies with indicated inhibitors. Scale bar, 200 μm.\
(B) Western blot for phospho-ERK5 (pERK5) after BMP-4 treatment in parental mESCs and a *Smad1/5* dKO line. Cells were starved overnight in N2B27 medium and stimulated with 100 ng/ml BMP-4 for indicated time periods.\
(C) Western blot for pERK5 in mESCs stably expressing MEK5 mutants or control GFP.\
(D) qRT-PCR analysis of mESCs stably expressing MEK5 mutants or control GFP. Data represent means ± SEM of three independent experiments; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus GFP.\
(E) Western blot for KLF2 in mESCs stably expressing MEK5 mutants or control GFP.\
(F) Proliferation and Td of mESCs stably expressing MEK5 mutants or control GFP maintained in LIF+serum+puromycin. A representative growth curve is shown. Td (mean ± SEM) was calculated using three independent experiments; ^∗^p \< 0.05 versus GFP.\
(G) Morphology (left) and AP activity (right) of mESCs transfected with MEK5DD or MEK1DD maintained in LIF+serum+puromycin. Scale bar, 200 μm.\
(H and I) Colony-forming assays of BL6-mESCs stably expressing MEK mutants or control GFP. Cells were maintained in LIF+MEK1/2i (H) and LIF+GSK3i (I) with indicated inhibitors for 5 days. (Left) Histograms show the percentage of undifferentiated, mixed, and differentiated colonies. (Right) The relative number of AP-positive colonies is presented. Data represent means ± SEM of at least three independent experiments. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001 versus GFP control.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}
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